TRVI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 09:30):

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions...

Stats
Today's Volume	573.00
Average Volume	306 000
Market Cap	196.54M
EPS	$0 ( 2024-03-20 )
Next earnings date	( $-0.0900 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.83
ATR14	$0.0160 (0.57%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-15	Galletta Christopher	Buy	28 500	Stock Option (right to buy)
2024-02-15	Simon Farrell	Buy	175 000	Stock Option (right to buy)
2024-02-15	Clark David J	Buy	175 000	Stock Option (right to buy)
2024-02-15	Good Jennifer L	Buy	630 000	Stock Option (right to buy)
2024-02-15	Sciascia Thomas	Buy	150 000	Stock Option (right to buy)

INSIDER POWER
79.67
Last 98 transactions
Buy: 31 017 280 \| Sell: 1 379 035

Volume Correlation

Long: 0.00 (neutral)

Short: 0.47 (neutral)

Signal:(32.767) Neutral

Trevi Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Trevi Therapeutics Inc Correlation - Currency/Commodity

-0.08
( neutral )

-0.42
( neutral )

0.00
( neutral )

-0.72
( moderate negative )

-0.27
( neutral )

-0.61
( weak negative )

Trevi Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-123 000 (0.00 %)
EPS:	$-0.290

Q4	2023
Revenue:	$0
Gross Profit:	$-35 000.00 (0.00 %)
EPS:	$-0.0786

Q3	2023
Revenue:	$0
Gross Profit:	$-35 000.00 (0.00 %)
EPS:	$-0.0775

Q2	2023
Revenue:	$0
Gross Profit:	$-34 000.00 (0.00 %)
EPS:	$-0.0724

Financial Reports:

No articles found.

Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.